Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)

Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) [Eur Heart J (2020); doi: 10.1093/eurheartj/ehaa612]. In the originally published version of this manuscript, several errors were noted and listed in this corrigendum. Upon original publication, Table 11, indicated that the reduction of Edoxaban doses was “30 mg o.d./15 mg o.d.” and the following drugs under concomitant use involved this reduction: “verapamil, quinidine or dronedarone”. The reduction of Edoxaban doses should have read: “30 mg o.d.”. The following drugs under concomitant use involving this reduction should have read: ”dronedarone, ciclosporine, erythromycin, or ketoconazole”. Upon the original publication, Figure 2, omitted the following: “Di Carlo, et al. Europace, 2019; 21:1468-1475. PMID: 31131389”. This has been added to the figure legend. Upon the original publication, Figure 3, included “(non-Caucasian)” Summary of risk factors for incident AF. This has now been deleted. Upon the original publication, there were inaccuracies within the text in the following areas: in footnote c to Figure 17; in the title and; in the "Authors/Task Force Members" footnote. These errors have now been corrected online. Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model